Dr. Pusztai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 George St, New Haven
Suite 120
New Haven, CT 06520Fax+1 203-785-5792
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1996 - 1999
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1992 - 1996
Semmelweis UniversityClass of 1986
Certifications & Licensure
CT State Medical License 2012 - 2025
TX State Medical License 1997 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2003
Clinical Trials
- Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients Start of enrollment: 2001 Jan 01
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
- Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Start of enrollment: 2003 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.Sherene Loi, Roberto Salgado, Giuseppe Curigliano, Roberto Iván Romero Díaz, Suzette Delaloge
Nature Medicine. 2025-01-21 - Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.Alejandro Rios-Hoyo, Kaitlyn Xiong, Jiawei Dai, Christina Yau, Michal Marczyk
Clinical Cancer Research. 2025-01-17 - GABAreceptor π forms channels that stimulate ERK through a G-protein-dependent pathway.Yueyue Wang, Yalan Zhang, Wenxue Li, Barbora Salovska, Jianan Zhang
Molecular Cell. 2025-01-02
Journal Articles
- Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women with ERBB2 (HER2)–Positive Breast CancerLajos Pusztai, MD, JAMA Network Open
- Association of T-cell Receptor Repertoire Use with Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast CancerSecondary Analysis of the NeoALTT...Lajos Pusztai, Jose Baselga, JAMA
Lectures
- Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Why Do We Care About Molecular Evolution in Breast Cancer?2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- 2013 Breast Cancer Symposium,American Society of Breast Surgeons, San Francisco, California - 9/7/2013
Press Mentions
RSClin Tool N+ Enhances Breast Cancer Risk EstimatesJanuary 23rd, 2025- RSClin® Tool N+ Enhances Accuracy in Recurrence Risk Estimation and Chemotherapy Benefit for Node-Positive Breast CancerJanuary 23rd, 2025
- Novel Prognostic Tool in Hormone Receptor–Positive, HER2-Negative, Node-Positive Breast CancerJanuary 3rd, 2025
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
